SNRNP200 — small nuclear ribonucleoprotein U5 subunit 200

The SNRNP200 gene provides instructions for making a crucial protein that acts like a molecular motor inside our cells. This protein is an essential part of a complex machine called the spliceosome. The spliceosome's job is to "edit" the genetic messages (RNA) copied from our DNA, cutting out unnecessary parts and pasting the important parts together so the cell can build working proteins. Because every cell in the body needs to edit these genetic messages, the SNRNP200 protein is found and used in almost all tissues. When there is a mutation (a spelling mistake) in the SNRNP200 gene, the molecular motor doesn't work perfectly. Even though this protein is used everywhere in the body, the mutation specifically affects the eyes, causing a condition called Retinitis Pigmentosa (RP). The light-sensing cells in the retina (the back of the eye) are highly active and need a massive amount of perfectly edited genetic messages to survive and function. When the editing process is slowed down or makes mistakes because of the mutated SNRNP200 protein, these retinal cells become stressed and gradually die off. For patients and families, a mutation in this gene means a diagnosis of autosomal dominant Retinitis Pigmentosa. "Autosomal dominant" means that a person only needs one mutated copy of the gene (inherited from one parent) to develop the disease, and they have a 50% chance of passing it on to each of their children. The disease usually starts with night blindness in childhood or early adulthood, followed by a slow loss of peripheral (side) vision, creating a "tunnel vision" effect. While there is currently no cure, knowing the specific gene involved helps doctors predict how the disease might progress and allows patients to participate in clinical trials for new, targeted treatments in the future.

Gene description: Encodes a component of the U5 snRNP, crucial for pre-mRNA splicing in various cells, including retinal cells.

Patient and family guide: The SNRNP200 gene provides instructions for making a crucial protein that acts like a molecular motor inside our cells. This protein is an essential part of a complex machine called the spliceosome. The spliceosome's job is to "edit" the genetic messages (RNA) copied from our DNA, cutting out unnecessary parts and pasting the important parts together so the cell can build working proteins. Because every cell in the body needs to edit these genetic messages, the SNRNP200 protein is found and used in almost all tissues. When there is a mutation (a spelling mistake) in the SNRNP200 gene, the molecular motor doesn't work perfectly. Even though this protein is used everywhere in the body, the mutation specifically affects the eyes, causing a condition called Retinitis Pigmentosa (RP). The light-sensing cells in the retina (the back of the eye) are highly active and need a massive amount of perfectly edited genetic messages to survive and function. When the editing process is slowed down or makes mistakes because of the mutated SNRNP200 protein, these retinal cells become stressed and gradually die off. For patients and families, a mutation in this gene means a diagnosis of autosomal dominant Retinitis Pigmentosa. "Autosomal dominant" means that a person only needs one mutated copy of the gene (inherited from one parent) to develop the disease, and they have a 50% chance of passing it on to each of their children. The disease usually starts with night blindness in childhood or early adulthood, followed by a slow loss of peripheral (side) vision, creating a "tunnel vision" effect. While there is currently no cure, knowing the specific gene involved helps doctors predict how the disease might progress and allows patients to participate in clinical trials for new, targeted treatments in the future.

Gene function: SNRNP200 is part of the U5 snRNP, a core component of the spliceosome, which is essential for the splicing of pre-mRNA into mature mRNA. In the retina, proper splicing is critical for the expression of numerous genes required for photoreceptor development, function, and survival, making its disruption detrimental.

Protein structure: The SNRNP200 gene encodes a large protein of 2,136 amino acids, known as the U5 small nuclear ribonucleoprotein 200 kDa helicase (hBrr2). The protein is characterized by a complex, multi-domain architecture that is essential for its function as an RNA helicase. It contains two prominent DExD/H-box ATPase/helicase modules arranged in tandem. The N-terminal helicase module is catalytically active and is responsible for the ATP-dependent unwinding of RNA duplexes. The C-terminal helicase module, while structurally similar, lacks catalytic activity but plays a crucial regulatory role, modulating the activity of the N-terminal domain and mediating protein-protein interactions. Each of the two helicase modules is followed by a Sec63-like domain, which is thought to be involved in binding RNA and regulating the helicase activity. The SNRNP200 protein does not function in isolation; it assembles into the large U5 snRNP complex, interacting directly with other core spliceosomal proteins such as PRPF8 and EFTUD2. This assembly is critical for its stability and proper positioning within the U4/U6-U5 tri-snRNP complex, allowing it to execute its precise role in unwinding the U4/U6 snRNA duplex during spliceosome activation.

Molecular function: The SNRNP200 gene encodes the U5 small nuclear ribonucleoprotein 200 kDa helicase, also known as hBrr2. This protein is a critical component of the spliceosome, the large macromolecular complex responsible for removing introns from pre-messenger RNA (pre-mRNA) and ligating exons together. Specifically, SNRNP200 is an integral part of the U5 snRNP and the U4/U6-U5 tri-snRNP complexes. It functions as a DExD/H-box RNA helicase, an enzyme that utilizes the energy from ATP hydrolysis to unwind RNA duplexes. The primary biochemical activity of SNRNP200 is to catalyze the ATP-dependent unwinding of the U4/U6 small nuclear RNA (snRNA) duplex. This unwinding event is an essential, highly regulated step in the activation of the spliceosome, allowing the U6 snRNA to pair with the 5' splice site of the pre-mRNA and with the U2 snRNA to form the catalytic center of the spliceosome. Without the helicase activity of SNRNP200, the spliceosome cannot transition into its catalytically active conformation, thereby halting pre-mRNA splicing. In the context of the retina, the precise molecular function of SNRNP200 is identical to its role in other tissues. However, photoreceptor cells have an exceptionally high demand for the rapid and accurate splicing of transcripts encoding proteins essential for phototransduction and structural maintenance. Mutations in SNRNP200 are thought to impair its helicase activity or its interactions with other spliceosomal components, leading to the accumulation of unspliced or mis-spliced transcripts. This splicing dysregulation ultimately causes cellular stress and the progressive apoptosis of photoreceptor cells, resulting in retinitis pigmentosa.

Expression pattern: The SNRNP200 gene is ubiquitously expressed across a wide range of human tissues and cell types, reflecting its fundamental role in the core pre-mRNA splicing machinery. It is transcribed in nearly all cells of the body, as the spliceosome is essential for the processing of most protein-coding transcripts. High levels of expression are observed in the brain, heart, liver, and other major organs, consistent with its requirement for basic cellular viability and function. Despite this ubiquitous expression pattern, mutations in SNRNP200 predominantly cause a tissue-specific phenotype restricted to the retina. Within the eye, SNRNP200 is highly expressed in the photoreceptor cells (both rods and cones) and the retinal pigment epithelium (RPE). The specific vulnerability of the retina to SNRNP200 mutations is thought to be due to the exceptionally high metabolic demand and rapid turnover of transcripts required for phototransduction and outer segment renewal in photoreceptors, making them particularly sensitive to subtle defects in splicing efficiency or fidelity.

Mutation spectrum: The mutation spectrum of the SNRNP200 gene in inherited retinal diseases is predominantly characterized by missense mutations. These single amino acid substitutions typically occur in highly conserved regions of the protein, particularly within the functional domains such as the DExD/H-box helicase domains and the Sec63-like domains. Because the gene is essential for survival, large deletions, nonsense mutations, or frameshift mutations that result in a complete loss of function (null alleles) are generally not observed in living patients, as they are presumed to be embryonic lethal. The pathogenic variants in SNRNP200 act via a dominant-negative mechanism or haploinsufficiency, leading to autosomal dominant retinitis pigmentosa (adRP). Several hotspot regions have been identified, notably around amino acid residues 681, 1087, and 1090, where multiple independent mutations have been reported. To date, there are dozens of known pathogenic or likely pathogenic variants documented in databases such as ClinVar and HGMD, all of which are associated with the RP33 phenotype. The mutations disrupt the delicate balance of spliceosome assembly and activation, causing retinal-specific disease despite the gene's ubiquitous expression.

Pathogenic variants: 1. p.Ser1087Leu (c.3260C>T) - A well-characterized missense mutation located in the Sec63-like domain of the N-terminal active helicase module. It is a frequent cause of autosomal dominant retinitis pigmentosa (RP33) and is known to impair the unwinding of U4/U6 snRNAs. 2. p.Arg1090Leu (c.3269G>T) - Another common missense mutation situated near p.Ser1087Leu in the Sec63-like domain. It similarly disrupts spliceosome activation and is strongly associated with the RP33 phenotype. 3. p.Arg681His (c.2041C>T) - A missense mutation that has been identified in multiple families with adRP. It affects a conserved residue and has been shown to alter the interaction of SNRNP200 with other spliceosomal components. 4. p.Tyr689Cys (c.2066A>G) - A pathogenic variant reported in patients with retinitis pigmentosa, contributing to the spectrum of mutations that destabilize the U5 snRNP complex. 5. p.Gly865Ser (c.2593G>A) - A missense mutation documented in clinical databases as causing adRP, further highlighting the vulnerability of specific functional domains within the SNRNP200 protein.

Clinical significance: Mutations in the SNRNP200 gene are primarily associated with autosomal dominant retinitis pigmentosa (adRP), specifically designated as retinitis pigmentosa 33 (RP33). This condition is characterized by the progressive degeneration of photoreceptor cells in the retina, leading to a gradual loss of vision. The clinical manifestation typically begins with nyctalopia (night blindness) in the first or second decade of life, followed by a progressive constriction of the visual field, eventually resulting in tunnel vision and, in many cases, legal blindness. The severity and progression of SNRNP200-associated retinopathy can vary significantly among affected individuals, even within the same family. However, recent in-depth clinical phenotyping studies have shown that in many patients, the central retina and macular function are relatively preserved until the sixth decade of life. This preservation of central vision for an extended period makes patients with SNRNP200 mutations potentially good candidates for future therapeutic interventions aimed at halting disease progression before central vision is lost. Systemic features are generally absent, as the disease is typically confined to the eye despite the ubiquitous expression of the gene.

Inheritance: Autosomal Dominant

Chromosomal location: 2q11.2

Genotype-phenotype correlations: Genotype-phenotype correlations in SNRNP200-associated retinitis pigmentosa (RP33) exhibit considerable variability. While all known pathogenic mutations in this gene cause autosomal dominant RP, the age of onset, rate of progression, and ultimate severity of vision loss can differ significantly even among individuals carrying the same mutation. For instance, patients with the p.Ser1087Leu or p.Arg1090Leu mutations, which are located in the Sec63-like domain of the N-terminal active helicase module, often present with classic early-onset nyctalopia followed by progressive visual field loss. However, studies comparing different families and cohorts have noted that the phenotypic expression is not strictly dictated by the specific variant. Environmental factors, genetic modifiers, and individual variations in the expression of other spliceosomal components likely play a role in modulating the disease severity. Some reports suggest that mutations affecting the ATP-binding or helicase activity more severely may correlate with a faster rate of retinal degeneration, but broad, consistent genotype-phenotype rules remain challenging to establish due to the rarity of the condition and the inherent clinical variability of adRP.

Research and therapeutic approaches: Currently, there are no FDA-approved therapies specifically targeted at curing or halting the progression of SNRNP200-associated retinitis pigmentosa. Management primarily focuses on supportive care, including the use of low-vision aids, mobility training, and regular ophthalmologic monitoring to manage complications such as cataracts or macular edema. While Luxturna (voretigene neparvovec-rzyl) is an approved gene therapy for IRDs, it is strictly indicated for patients with biallelic RPE65 mutations and is not applicable to those with SNRNP200 mutations. However, the pipeline for therapeutic strategies targeting adRP, including those caused by SNRNP200, is actively expanding. Because SNRNP200 mutations typically act via a dominant-negative mechanism, traditional gene augmentation therapy (simply adding a healthy copy of the gene) is often insufficient. Instead, investigational approaches are focusing on gene editing technologies, such as CRISPR/Cas9, to specifically knock out or correct the mutant allele while leaving the wild-type allele intact. Other pipeline strategies include the use of antisense oligonucleotides (ASOs) to modulate splicing or degrade the mutant transcript, and neuroprotective agents aimed at prolonging photoreceptor survival regardless of the underlying genetic defect. Several of these approaches are currently in preclinical development using animal models, with the hope of advancing to human clinical trials in the future.

Diagnostic testing: Diagnostic testing for SNRNP200-associated retinitis pigmentosa typically involves comprehensive genetic screening. Given the genetic heterogeneity of inherited retinal diseases, testing is most commonly performed using targeted next-generation sequencing (NGS) panels that include SNRNP200 along with other known IRD genes. Whole exome sequencing (WES) or whole genome sequencing (WGS) may also be utilized, particularly in cases where panel testing is inconclusive or when a novel variant is suspected. Genetic counseling is a critical component of the diagnostic process for individuals with SNRNP200 mutations. Because the condition is inherited in an autosomal dominant manner, affected individuals have a 50% chance of passing the mutated gene to each of their children. Counselors must discuss the implications of the diagnosis, the variable expressivity and incomplete penetrance that can occur, and the potential impact on family planning. Additionally, identifying the specific mutation can help in predicting the disease course and determining eligibility for future clinical trials or targeted therapies.

Animal models: Animal models have been crucial in elucidating the role of SNRNP200 in retinal health and disease. In zebrafish, knockdown of the snrnp200 ortholog results in severe developmental defects, including a curved body shape, cardiac edema, and shortened body length, highlighting its essential role in early development. Specifically in the eye, snrnp200 knockdown leads to the demorphogenesis of rod photoreceptors and increased apoptosis in the retina, mimicking the degenerative phenotype seen in human patients. In mice, the International Mouse Phenotyping Consortium (IMPC) has shown that complete knockout of the Snrnp200 gene is homozygous-lethal, indicating that the gene is essential for embryonic survival. This lethality underscores the fundamental requirement of SNRNP200 in general cellular function, despite the fact that human mutations primarily manifest as a tissue-specific retinal disease. Heterozygous mouse models and Drosophila models have also been developed to study the specific mechanisms by which mutant SNRNP200 disrupts spliceosome assembly and leads to photoreceptor degeneration.

Population genetics: Mutations in the SNRNP200 gene are a rare cause of autosomal dominant retinitis pigmentosa (adRP), accounting for a small percentage of all adRP cases worldwide. Because the disease is rare and inherited in a dominant manner, the carrier frequency in the general population is extremely low. There are no widely recognized founder mutations that lead to a high prevalence in specific ethnic groups; instead, pathogenic variants have been identified in diverse populations, including European, Asian, and American cohorts. The variants are typically private to specific families or shared among a small number of unrelated individuals, reflecting the broad mutational spectrum of the gene.

Selected references: 1. Zhao C, et al. Autosomal-Dominant Retinitis Pigmentosa Caused by a Mutation in SNRNP200, a Gene Required for Unwinding of U4/U6 snRNAs. Am J Hum Genet, 2009. PMID: 19896112 2. Zhang X, et al. Contribution of SNRNP200 sequence variations to retinitis pigmentosa. Eye (Lond), 2013. PMID: 23929064 3. Romo-Aguas JC, et al. SNRNP200-Associated Retinopathy: In-Depth Clinical Phenotyping and Genotype-Phenotype Correlation. Am J Ophthalmol, 2025. PMID: 39890000 4. Zhang T, et al. SNRNP200 Mutations Cause Autosomal Dominant Retinitis Pigmentosa. Front Med (Lausanne), 2021. PMID: 33614682 5. Liu Y, et al. Knocking Down Snrnp200 Initiates Demorphogenesis of Rod Photoreceptors. PLoS One, 2015. PMID: 26079834 6. Wood KA, et al. The Role of the U5 snRNP in Genetic Disorders and Cancer. Front Genet, 2021. PMID: 33717319 7. O'Neal TB, et al. Retinitis Pigmentosa. StatPearls, 2024. PMID: 30085562